Elicio Therapeutics Inc
Elicio Therapeutics Inc (ELTX) Implied Volatility Current
ELTX's 30 day implied volatility is 264.93%, with an IV Rank of 63.49%. This is an average IV Rank versus the past year, meaning Elicio Therapeutics Inc options are fairly priced and currently offer no clear edge to buyers or sellers. ELTX's 30 day historical volatility sits at 95.85%, which means implied volatility is running 169.08 points above historical volatility, as of Nov 16, 2026.
Read more
Tracking ELTX implied volatility helps you spot when Elicio Therapeutics Inc options are historically cheap or expensive, and where the best trades are hiding. When ELTX IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor ELTX implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking ELTX IV rank helps you see whether ELTX's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.
Implied Volatility
IV is slightly elevated. Premiums are richer, leaning toward sellers.
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →